Antares Pharma, Inc. (ATRS)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Antares Pharma, Inc. (ATRS) trades at $5.59 with AI Score 56/100 (Hold). Antares Pharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative drug delivery systems. Market cap: 0, Sector: Healthcare.
Last analyzed: Feb 9, 2026Antares Pharma, Inc. (ATRS) Healthcare & Pipeline Overview
Antares Pharma revolutionizes drug delivery with innovative auto-injector technology, targeting significant therapeutic areas and driving growth through strategic partnerships and a robust portfolio of proprietary and generic injectable products, offering investors a notable opportunity in the specialty pharmaceutical sector.
Investment Thesis
Antares Pharma presents a notable research candidate due to its focus on innovative drug delivery systems and a diversified portfolio of both proprietary and generic injectable products. The company's strategic partnerships with major pharmaceutical companies enhance its market reach and development capabilities. With a P/E ratio of 20.55 and a strong gross margin of 62.9%, Antares demonstrates financial stability and profitability. Growth catalysts include the continued expansion of XYOSTED in the testosterone replacement therapy market and the development of new drug/device products for urologic oncology, immunology, and endocrinology. The company's commitment to addressing unmet patient needs in targeted therapeutic areas positions it for sustained growth and value creation.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 62.9% indicates strong pricing power and efficient cost management.
- Profit Margin of 25.2% reflects healthy profitability and operational efficiency.
- P/E Ratio of 20.55 suggests a reasonable valuation relative to earnings.
- Strategic alliances with Pfizer, Teva, and Idorsia provide access to broader markets and development resources.
- Focus on innovative drug delivery systems provides a competitive edge in the specialty pharmaceutical market.
Competitors & Peers
Strengths
- Innovative drug delivery technologies.
- Strong portfolio of injectable products.
- Strategic partnerships with major pharmaceutical companies.
- Established manufacturing capabilities.
Weaknesses
- Reliance on partnerships for commercialization.
- Competition from larger pharmaceutical companies.
- Dependence on regulatory approvals for new products.
- Subsidiary of Halozyme Therapeutics, potential for resource allocation changes.
Catalysts
- Regulatory approvals for new drug/device products.
- Expansion of XYOSTED market share.
- Leveraging strategic partnerships for product development and commercialization.
- Continued growth in the market for injectable drugs.
Risks
- Competition from generic drug manufacturers.
- Changes in healthcare regulations.
- Product liability claims.
- Dependence on regulatory approvals for new products.
- Reliance on partnerships for commercialization.
Growth Opportunities
- Expansion of XYOSTED Market: XYOSTED, for testosterone replacement therapy, holds significant growth potential. The market for testosterone replacement therapy is projected to grow as the population ages and awareness of hypogonadism increases. Antares can expand its market share through targeted marketing and increased physician awareness. This represents a multi-million dollar market opportunity with ongoing growth potential.
- Development of New Drug/Device Products: Antares is actively developing new drug/device products for urologic oncology, immunology, and endocrinology. These new products have the potential to address unmet needs in these therapeutic areas and generate significant revenue. The timeline for development and commercialization varies, but successful launches could drive substantial growth within the next 3-5 years.
- Strategic Partnerships: Antares' strategic alliances with Pfizer, Teva, and Idorsia provide access to broader markets and development resources. These partnerships can accelerate the development and commercialization of new products and expand the company's geographic reach. Leveraging these partnerships will be ongoing and crucial for sustained growth.
- Pen Injector Technology: Antares develops disposable pen injectors for diabetes and osteoporosis. The diabetes market is experiencing substantial growth, and the osteoporosis market is also significant due to the aging population. Expanding the application of pen injector technology represents a substantial growth opportunity over the next several years.
- TLANDO Commercialization: TLANDO, indicated for testosterone deficiency, represents a significant growth opportunity. Successful commercialization of TLANDO could generate substantial revenue. The timeline for market penetration depends on regulatory approvals and marketing efforts, but it could become a key revenue driver within the next 2-3 years.
Opportunities
- Expansion into new therapeutic areas.
- Development of new drug/device products.
- Increased adoption of auto-injector technology.
- Growth in the market for injectable drugs.
Threats
- Competition from generic drug manufacturers.
- Changes in healthcare regulations.
- Product liability claims.
- Patent expirations.
Competitive Advantages
- Proprietary drug delivery technologies.
- Strategic partnerships with major pharmaceutical companies.
- Established manufacturing capabilities.
- Portfolio of both proprietary and generic products.
About ATRS
Antares Pharma, Inc., founded in 1979 and headquartered in Ewing, New Jersey, is a specialty pharmaceutical company dedicated to the development and commercialization of pharmaceutical products and technologies that address specific patient needs. The company has carved a niche for itself by focusing on innovative drug delivery systems, particularly injectable products. Antares develops, manufactures, and commercializes a range of novel therapeutic products. Key products include XYOSTED, a subcutaneous injection for testosterone replacement therapy in adult males; OTREXUP, a subcutaneous methotrexate injection for rheumatoid arthritis, juvenile idiopathic arthritis and psoriasis; and NOCDURNA, a sublingual tablet for nocturia. The company also offers generic Epinephrine Injection USP for severe allergic reactions, Sumatriptan Injection USP for migraine and cluster headaches, and Makena subcutaneous auto-injector to reduce the risk of preterm birth. Additionally, Antares develops disposable pen injectors for diabetes and osteoporosis, QuickShot auto-injectors, and TLANDO for testosterone deficiency. Antares Pharma was acquired by Halozyme Therapeutics, Inc. on May 23, 2022, and now operates as a subsidiary. The company has established strategic alliances with major players like Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG, further solidifying its market position.
What They Do
- Develops innovative drug delivery systems.
- Manufactures injectable pharmaceutical products.
- Commercializes proprietary and generic injectable products.
- Offers XYOSTED for testosterone replacement therapy.
- Provides OTREXUP for rheumatoid arthritis and psoriasis.
- Markets NOCDURNA for nocturia.
- Develops auto-injectors for various therapies.
Business Model
- Develops and manufactures proprietary pharmaceutical products.
- Generates revenue through product sales.
- Partners with other pharmaceutical companies for development and commercialization.
- Out-licenses its drug delivery technologies.
Industry Context
Antares Pharma operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and increasing demand for advanced drug delivery technologies. The market for injectable drugs is expanding, driven by the rising prevalence of chronic diseases and the need for targeted therapies. Competition includes companies like Albireo Pharma (ALBO), Atrion Corporation (ATRI), Cassava Sciences (CSII), and Lineage Cell Therapeutics (BTX). Antares differentiates itself through its focus on auto-injector technology and strategic partnerships, positioning it to capitalize on the growing demand for convenient and effective drug delivery solutions.
Key Customers
- Patients requiring injectable medications.
- Physicians prescribing injectable therapies.
- Pharmacies dispensing pharmaceutical products.
- Pharmaceutical companies partnering with Antares.
ATRS Financials
ATRS Price Today & Live Chart
Antares Pharma, Inc. (ATRS) stock price: $5.59 (+0.01, +0.18%)
ATRS Latest News
-
Stocks That Hit 52-Week Highs On Monday
· Feb 8, 2021
-
The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market
· Jan 26, 2021
-
Stocks That Hit 52-Week Highs On Monday
· Jan 25, 2021
-
Stocks That Hit 52-Week Lows On Monday
· Mar 23, 2020
ATRS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATRS.
Price Targets
Wall Street price target analysis for ATRS.
ATRS MoonshotScore
What does this score mean?
The MoonshotScore rates ATRS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Stocks That Hit 52-Week Highs On Monday
The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market
Stocks That Hit 52-Week Highs On Monday
Stocks That Hit 52-Week Lows On Monday
ATRS Healthcare Stock FAQ
What does Antares Pharma, Inc. do?
Antares Pharma, Inc. is a specialty pharmaceutical company that focuses on developing and commercializing innovative drug delivery systems, primarily injectable products. The company offers a range of proprietary and generic injectable products, including XYOSTED for testosterone replacement therapy, OTREXUP for rheumatoid arthritis, and NOCDURNA for nocturia. Antares also develops auto-injectors and pen injectors for various therapies. The company generates revenue through product sales and strategic partnerships with major pharmaceutical companies, addressing unmet patient needs in targeted therapeutic areas.
Is ATRS stock worth researching?
Evaluating Antares Pharma (ATRS) requires considering its financial metrics, growth potential, and risks. The company's gross margin of 62.9% and profit margin of 25.2% indicate strong profitability. Growth catalysts include the expansion of XYOSTED and the development of new drug/device products. However, potential risks include competition from generic drug manufacturers and dependence on regulatory approvals. Given these factors, ATRS could be worth researching for investors seeking exposure to the specialty pharmaceutical sector with a focus on innovative drug delivery systems.
What are the main risks for ATRS?
The main risks for Antares Pharma include competition from generic drug manufacturers, which could erode market share and pricing power. Changes in healthcare regulations could also impact the company's business model and profitability. Product liability claims represent another significant risk, particularly for injectable products. Additionally, the company's dependence on regulatory approvals for new products and reliance on partnerships for commercialization create potential vulnerabilities. These factors should be carefully considered when evaluating the investment potential of ATRS.
What are the key factors to evaluate for ATRS?
Antares Pharma, Inc. (ATRS) currently holds an AI score of 56/100, indicating moderate score. The stock trades at a P/E of 20.5x, near the S&P 500 average (~20-25x). Key strength: Innovative drug delivery technologies. Primary risk to monitor: Competition from generic drug manufacturers. This is not financial advice.
How frequently does ATRS data refresh on this page?
ATRS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ATRS's recent stock price performance?
Recent price movement in Antares Pharma, Inc. (ATRS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative drug delivery technologies. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ATRS overvalued or undervalued right now?
Determining whether Antares Pharma, Inc. (ATRS) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 20.5. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ATRS?
Before investing in Antares Pharma, Inc. (ATRS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Stock data pending update.
- Information is based on available sources and may not reflect the most recent developments.